MX9304310A - ANTIGENS IN THE FORM OF PARTICLES AND METHOD FOR ITS PRODUCTION. - Google Patents

ANTIGENS IN THE FORM OF PARTICLES AND METHOD FOR ITS PRODUCTION.

Info

Publication number
MX9304310A
MX9304310A MX9304310A MX9304310A MX9304310A MX 9304310 A MX9304310 A MX 9304310A MX 9304310 A MX9304310 A MX 9304310A MX 9304310 A MX9304310 A MX 9304310A MX 9304310 A MX9304310 A MX 9304310A
Authority
MX
Mexico
Prior art keywords
particles
antigens
virus
production
relates
Prior art date
Application number
MX9304310A
Other languages
Spanish (es)
Inventor
Polly Roy
Original Assignee
Oxford University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215101A external-priority patent/GB9215101D0/en
Application filed by Oxford University filed Critical Oxford University
Publication of MX9304310A publication Critical patent/MX9304310A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta invención se relaciona con antígenos en forma partículasespecialmente antígenos en la forma de partículas similares al virus opartículas similares al núcleo de un virus. La invención se relacionaparticularmente con antígenos quiméricos en los que los epítopes extrañosse presentan sobre o dentro de partículas similares al virus o partículassimilares al núcleo de un virus.This invention relates to antigens in particle form, especially antigens in the form of virus-like particles or virus-like nucleic particles. The invention relates particularly to chimeric antigens in which foreign epitopes are present on or within virus-like particles or particles similar to the nucleus of a virus.

MX9304310A 1992-07-16 1993-07-16 ANTIGENS IN THE FORM OF PARTICLES AND METHOD FOR ITS PRODUCTION. MX9304310A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929215101A GB9215101D0 (en) 1992-07-16 1992-07-16 Multiple particulate antigen delivery system
US97115892A 1992-11-04 1992-11-04

Publications (1)

Publication Number Publication Date
MX9304310A true MX9304310A (en) 1995-01-31

Family

ID=26301262

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304310A MX9304310A (en) 1992-07-16 1993-07-16 ANTIGENS IN THE FORM OF PARTICLES AND METHOD FOR ITS PRODUCTION.

Country Status (6)

Country Link
CN (1) CN1084218A (en)
AU (1) AU4773293A (en)
IL (1) IL106362A (en)
MX (1) MX9304310A (en)
PT (1) PT101310A (en)
WO (1) WO1994002173A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ312502A (en) * 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
WO1997002835A1 (en) * 1995-07-07 1997-01-30 Oravax, Inc. Intranasal vaccination against gastrointestinal disease
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
JP2003504014A (en) * 1999-06-30 2003-02-04 エボテック オーアーイー アクチェンゲゼルシャフト Viral particles, their preparation and preferably their use in pharmaceutical screening and functional genomes
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
EP1219705B1 (en) * 2000-12-29 2007-11-28 Evotec AG Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US11053509B2 (en) 2016-04-19 2021-07-06 Csir Plant-produced chimaeric Orbivirus VLPs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens

Also Published As

Publication number Publication date
PT101310A (en) 1994-05-31
CN1084218A (en) 1994-03-23
WO1994002173A1 (en) 1994-02-03
AU4773293A (en) 1994-02-14
IL106362A0 (en) 1993-11-15
IL106362A (en) 1998-12-06

Similar Documents

Publication Publication Date Title
ATE224184T1 (en) METHOD FOR MICROENCAPSULATING ANTIGENS AND USE OF THE COMPOSITIONS AS VACCINES
ATE505542T1 (en) TUMOR-ASSOCIATED ANTIGEN DERIVATIVES OF THE MAGE FAMILY FOR THE PRODUCTION OF FUSION PROTEINS WITH T-HELPER EPITOPES AND COMPOSITIONS FOR VACCINATION
HUP9800730A3 (en) System for the expression of heterologous antigens as fusion proteins
IT8220616A0 (en) PROCEDURE FOR THE MANUFACTURE OF CONTAINERS FOR GAS AND FLUIDS BY ASSEMBLY OF PREFABRICATED PARTS.
CO4480111A1 (en) MONOCLONAL MONO SPECIFIC ANTIBODIES FOR HUMANS B7. AND / OR B7.2, PRIMATIZED FORMS OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, AND USE OF THE SAME AS IMMUNOSUPPRESSANTS
NO933798D0 (en) CERAMIC GRINDING GRINES, PROCEDURE FOR THE MANUFACTURE OF SUCH AS, AND GRINDING PRODUCTS MADE FROM SUCH
IT8419729A0 (en) PROCEDURE FOR THE PREPARATION OF LYOPHILIZED ADSORBED MULTI-PURPOSE VACCINES.
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
NO20002504L (en) Adenovirus vectors and method of reducing homologous recombination phenomena
MX9304310A (en) ANTIGENS IN THE FORM OF PARTICLES AND METHOD FOR ITS PRODUCTION.
AR245496A1 (en) Cleaning compound for hard surfaces.
BR9902287B1 (en) method for inspecting dimensional characteristics of a container mouth and system for the manufacture of glassware.
PT1053017E (en) VACCINES UNDERSTANDING INTERLEUCIN-12 AND HERPES SIMPLEX VIRUS ANTIGEN
ES510897A0 (en) METHOD OF FORMING A GLASS COMPOSITION THAT HAS PORTIONS OF SILICON AND ALUMINUM OXIDE.
NL192214B (en) Cladding for tunnels, open stone corridors and the like.
TR26964A (en) The method for centrifuging wet glasses.
ES2196150T3 (en) IMMUNOLOGICAL TOLERANCE INDUCTION BY THE USE OF ANTI-CD4 ANTIBODIES THAT DO NOT INDUCE DEPLOYMENT.
NO922622D0 (en) BIOMASS FOR PRODUCING THE VIRUS / VIRUS ANTIGEN
ES2236703T3 (en) USE OF METHODS TO IDENTIFY HYDROPHYL SIGNAL OLIGOPEPTIDES.
GR930100091A (en) Process for obtaining olive oil.
DE69107744D1 (en) Radiation-shielding heavy concrete, particularly suitable for the production of containers for radioactive waste.
DE59902807D1 (en) EXPANDED POLYPROPYLENE PARTICLES
IT1247590B (en) METHOD FOR THE ASSEMBLY OF STRUCTURES, IN PARTICULAR AERONAUTICAL STRUCTURES.
DK0790004T3 (en) Mineral preparation containing coral sand or corallite
ITRM910385A0 (en) VACCINES USING ERYTHROCYTES AS VEHICLES OF ANTIGENS.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal